Harpoon Therapeutics
OverviewSuggest Edit
Harpoon Therapeutics is an immuno-oncology company which uses a proprietary technology platform focused on T cell engagement to discover and develop novel biologics for the treatment of cancer and other diseases. The Company has designed a novel antibody-based drug discovery platform called TriTAC™ that unleashes the target cell killing properties of a patient’s own immune system through T cell activation.
TriTAC™ antibodies are designed to simultaneously bind to cancer cells and T cells, causing the attached T cells to release toxic factors leading to destruction of the attached target cell. In addition, TriTAC™ antibodies are engineered to bind to human serum albumin which allows for less frequent dosing, and their relatively small size allows for improved penetration into tumor tissue.
| Type | Public | |
| Founded | 2015 | |
| HQ | South San Francisco, CA, US | Map |
| Website | harpoontx.com | |
| Employee Ratings | More |
Recent NewsAll News
- Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer
- Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome
- Harpoon Therapeutics Announces Leadership Change
- Harpoon Therapeutics to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference
Key People/Management at Harpoon Therapeutics
Julie Eastland
President and Chief Executive Officer
Natalie R. Sacks
Chief Medical Officer
Susan Dana Jones
Senior Vice President, Product Development
Rick Austin
Vice President, Research
Holger Wesche
Chief Scientific Officer
Georgia L. Erbez
Chief Financial Officer
Harpoon Therapeutics Office Locations
Harpoon Therapeutics has offices in South San Francisco and Louisville
South San Francisco, CA, US (HQ)
4000 Shoreline Ct #250
Louisville, KY, US
462 S 4th St
South San Francisco, CA, US
131 Oyster Point Blvd #300
Harpoon Therapeutics Financials and Metrics
Harpoon Therapeutics Revenue
Harpoon Therapeutics's revenue was reported to be $708 k in FY, 2017
| USD | |
|---|---|
Market capitalization (11-May-2022) | 69.5m |
Closing stock price (11-May-2022) | 1.8 |
Cash (31-Dec-2020) | 21.2m |
EV | 61.8m |
Harpoon Therapeutics's current market capitalization is $69.5 m.
Annual
Annual
Quarterly
| USD | Q3, 2017 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|
Net Income | (11.9m) | (17.6m) | (13.6m) | (25.4m) | (41.3m) | (12.6m) | (25.2m) | (38.6m) |
Depreciation and Amortization | 244.0k | 447.0k | 297.0k | 596.0k | 400.0k | 503.0k | 1.0m | 1.5m |
Accounts Payable | (12.0k) | (10.0k) | (771.0k) | (876.0k) | (697.0k) | (1.1m) | (1.0m) | (815.0k) |
Cash From Operating Activities | (10.9m) | (20.7m) | (12.4m) | (25.4m) | (36.6m) | (17.5m) | 20.0m | 6.6m |
| USD | FY, 2016 |
|---|---|
Financial Leverage | 1.9 x |
Harpoon Therapeutics Cybersecurity Score
Harpoon Therapeutics Environment, Social & Governance (ESG) Ratings
Harpoon Therapeutics Online and Social Media Presence
Harpoon Therapeutics's Trends
Harpoon Therapeutics News and Updates
May 02, 2022
Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer
HPN328, Harpoon’s DLL3-targeting T cell engager, to be evaluated in combination with anti-PD-L1 antibody in patients with small cell lung cancer HPN328, Harpoon’s DLL3-targeting T cell engager, to be evaluated in combination with anti-PD-L1 antibody in patients with small cell lung cancer
April 12, 2022
Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome
TriTAC-XR demonstrates extended release mechanism that confirms accumulation of active drug which improves therapeutic index TriTAC-XR demonstrates extended release mechanism that confirms accumulation of active drug which improves therapeutic index
April 07, 2022
Harpoon Therapeutics Announces Leadership Change
SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that Natalie Sacks, M.D., Chief Medical Officer, will be leaving the company effective June 1, 2022. D…
April 07, 2022
Harpoon Therapeutics to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference
SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virt…
March 07, 2022
Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN328, a del…
January 11, 2022
Harpoon Therapeutics Provides Pipeline Development Milestones for 2022
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a pipeline milestone update on its TriTAC development programs.
Harpoon Therapeutics Blogs
May 12, 2022
Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Content Import
Thu, 05/12/2022 - 16:05
Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022
Earnings
…
March 10, 2022
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Content Import
Thu, 03/10/2022 - 16:06
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 10, 2022…
March 02, 2022
Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217
SOUTH SAN FRANCISCO, Calif. , March 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HPN217, a
November 12, 2021
Harpoon Therapeutics Presents Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer
Preclinical data demonstrates that extended-release TriTAC-XR T cell engager platform could mitigate toxicities, such as cytokine release syndrome SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company
November 10, 2021
Harpoon Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate
November 09, 2021
Harpoon Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Nov. 09, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that management will participate in two upcoming virtual investor conferences: A fireside
Harpoon Therapeutics Frequently Asked Questions
When was Harpoon Therapeutics founded?
Harpoon Therapeutics was founded in 2015.
Who are Harpoon Therapeutics key executives?
Harpoon Therapeutics's key executives are Julie Eastland, Natalie R. Sacks and Susan Dana Jones.
How many employees does Harpoon Therapeutics have?
Harpoon Therapeutics has 45 employees.
Who are Harpoon Therapeutics competitors?
Competitors of Harpoon Therapeutics include Enara Bio, Aeglea and ImmunoGen.
Where is Harpoon Therapeutics headquarters?
Harpoon Therapeutics headquarters is located at 4000 Shoreline Ct #250, South San Francisco.
Where are Harpoon Therapeutics offices?
Harpoon Therapeutics has offices in South San Francisco and Louisville.
How many offices does Harpoon Therapeutics have?
Harpoon Therapeutics has 3 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies